Austar Lifesciences Beheer
Beheer criteriumcontroles 3/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Mars Ho
Algemeen directeur
CN¥935.0k
Totale compensatie
| Percentage CEO-salaris | 98.3% |
| Dienstverband CEO | 10.8yrs |
| Eigendom CEO | 66.3% |
| Management gemiddelde ambtstermijn | 10.4yrs |
| Gemiddelde ambtstermijn bestuur | 10.4yrs |
Recente managementupdates
Recent updates
Austar Lifesciences Limited's (HKG:6118) Share Price Boosted 32% But Its Business Prospects Need A Lift Too
Oct 16
Investors Aren't Buying Austar Lifesciences Limited's (HKG:6118) Revenues
Aug 28We Think Shareholders May Want To Consider A Review Of Austar Lifesciences Limited's (HKG:6118) CEO Compensation Package
May 24Revenues Working Against Austar Lifesciences Limited's (HKG:6118) Share Price Following 30% Dive
Apr 18Would Austar Lifesciences (HKG:6118) Be Better Off With Less Debt?
Mar 28Investors Still Aren't Entirely Convinced By Austar Lifesciences Limited's (HKG:6118) Revenues Despite 25% Price Jump
Feb 12Market Cool On Austar Lifesciences Limited's (HKG:6118) Revenues
Dec 22We Think Austar Lifesciences (HKG:6118) Has A Fair Chunk Of Debt
Sep 28Here's Why Austar Lifesciences (HKG:6118) Has A Meaningful Debt Burden
Mar 31Austar Lifesciences Limited (HKG:6118) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Sep 19Is Austar Lifesciences (HKG:6118) A Risky Investment?
Apr 06Austar Lifesciences (HKG:6118) Has A Pretty Healthy Balance Sheet
Oct 24With EPS Growth And More, Austar Lifesciences (HKG:6118) Is Interesting
Sep 27If You Like EPS Growth Then Check Out Austar Lifesciences (HKG:6118) Before It's Too Late
May 31Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly
Mar 31Is Now The Time To Put Austar Lifesciences (HKG:6118) On Your Watchlist?
Mar 01Austar Lifesciences Limited (HKG:6118) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?
Feb 01
Are Austar Lifesciences's (HKG:6118) Statutory Earnings A Good Guide To Its Underlying Profitability?
Jan 11Austar Lifesciences (HKG:6118) Seems To Use Debt Quite Sensibly
Dec 21Can You Imagine How Jubilant Austar Lifesciences' (HKG:6118) Shareholders Feel About Its 191% Share Price Gain?
Dec 07Here's What Austar Lifesciences Limited's (HKG:6118) Shareholder Ownership Structure Looks Like
Nov 23Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -CN¥19m |
| Mar 31 2024 | n/a | n/a | -CN¥26m |
| Dec 31 2023 | CN¥935k | CN¥919k | -CN¥33m |
| Jun 30 2023 | n/a | n/a | CN¥51m |
| Mar 31 2023 | n/a | n/a | CN¥78m |
| Dec 31 2022 | CN¥895k | CN¥880k | CN¥104m |
| Sep 30 2022 | n/a | n/a | CN¥96m |
| Jun 30 2022 | n/a | n/a | CN¥105m |
| Mar 31 2022 | n/a | n/a | CN¥191m |
| Dec 31 2021 | CN¥865k | CN¥850k | CN¥277m |
| Sep 30 2021 | n/a | n/a | CN¥258m |
| Jun 30 2021 | n/a | n/a | CN¥238m |
| Mar 31 2021 | n/a | n/a | CN¥136m |
| Dec 31 2020 | CN¥927k | CN¥911k | CN¥33m |
| Sep 30 2020 | n/a | n/a | CN¥25m |
| Jun 30 2020 | n/a | n/a | CN¥17m |
| Mar 31 2020 | n/a | n/a | CN¥12m |
| Dec 31 2019 | CN¥918k | CN¥902k | CN¥8m |
| Sep 30 2019 | n/a | n/a | CN¥8m |
| Jun 30 2019 | n/a | n/a | CN¥8m |
| Mar 31 2019 | n/a | n/a | CN¥4m |
| Dec 31 2018 | CN¥880k | CN¥865k | CN¥107k |
| Sep 30 2018 | n/a | n/a | -CN¥16m |
| Jun 30 2018 | n/a | n/a | -CN¥33m |
| Mar 31 2018 | n/a | n/a | -CN¥43m |
| Dec 31 2017 | CN¥1m | CN¥1m | -CN¥54m |
Compensatie versus markt: De totale vergoeding ($USD 130.30K ) Mars } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de Hong Kong markt ($USD 233.82K ).
Compensatie versus inkomsten: De vergoeding van Mars is gestegen terwijl het bedrijf verliesgevend is.
CEO
Mars Ho (62 yo)
10.8yrs
Tenure
CN¥935,000
Compensatie
Mr. Kwok Keung Ho, also known as Mars, is the Founder of Austar Lifesciences Limited and serves as its Chairman of the Board and Chief Executive Officer. Mr. Ho is responsible for overseeing the business,...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder | no data | CN¥935.00k | 66.27% HK$ 207.2m | |
| Executive Director | 10.4yrs | CN¥2.13m | geen gegevens | |
| Executive Director | 10.4yrs | CN¥1.11m | geen gegevens | |
| Executive Director | 10.4yrs | CN¥2.26m | 7.27% HK$ 22.7m | |
| Vice President of Corporate Development | 3.9yrs | geen gegevens | geen gegevens | |
| Company Secretary | 2.1yrs | geen gegevens | geen gegevens |
10.4yrs
Gemiddelde duur
58yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van 6118 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 10.4 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder | 10.8yrs | CN¥935.00k | 66.27% HK$ 207.2m | |
| Executive Director | 10.4yrs | CN¥2.13m | geen gegevens | |
| Executive Director | 10.4yrs | CN¥1.11m | geen gegevens | |
| Executive Director | 10.8yrs | CN¥2.26m | 7.27% HK$ 22.7m | |
| Independent Non-Executive Director | 10.1yrs | CN¥161.00k | geen gegevens | |
| Independent Non-Executive Director | 7.1yrs | CN¥161.00k | geen gegevens | |
| Independent Non-Executive Director | 10.1yrs | CN¥161.00k | geen gegevens | |
| Non-Executive Director | 10.4yrs | CN¥632.00k | geen gegevens |
10.4yrs
Gemiddelde duur
51.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van 6118 zijn ervaren en ervaren (gemiddelde ambtstermijn van 10.4 jaar).